Biotech
Freenome
Freenome raises $270M Series C at $1.1B valuation
$270M
Total Raised
Series C
Latest Round
2014
Founded
300+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$1.1B
Latest Round Size
$270M
Latest Round Date
February 2021
Freenome: Series C Funding Round
Freenome has successfully raised $270M in Series C funding, reaching a valuation of $1.1B.
Company Overview
Early cancer detection using AI
Funding Details
The Series C round was led by T. Rowe Price, with participation from Perceptive Advisors.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- T. Rowe Price: Verified investor in Series C
- Perceptive Advisors: Verified investor in Series C
Key Investors
T. Rowe Price
Lead Investor
Verified investor in Series C
Perceptive Advisors
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M